Literature DB >> 24487064

A non-canonical function of eukaryotic elongation factor 1A1: regulation of interleukin-6 expression.

Ingo Schulz1, Claudia Engel1, André J Niestroj1, Astrid Kehlen1, Jens-Ulrich Rahfeld2, Martin Kleinschmidt2, Karola Lehmann3, Steffen Roßner4, Hans-Ulrich Demuth5.   

Abstract

Interleukin-6 is one of the most prominent triggers of inflammatory processes. We have shown recently that heteroarylketones (HAKs) interfere with stimulated interleukin-6 expression in astrocytes by suppression of STAT3 phosphorylation at serine 727. Surprisingly, this effect is not based on the inhibition of STAT3-relevant kinases. Therefore, we here used the structurally modified HAK compound biotin-HAK-3 in a reverse chemical approach to identify the relevant molecular target in UV-mediated cross-linking experiments. Employing streptavidin-specific 2D-immunoblotting followed by mass spectrometry we identified nine proteins putatively interacting with biotin-HAK-3. After co-immunoprecipitation, co-immunofluorescence, surface plasmon resonance analyses and RNAi-mediated knock-down, the eukaryotic elongation factor 1A1 (eEF1A1) was verified as the relevant target of HAK bioactivity. eEF1A1 forms complexes with STAT3 and PKCδ, which are crucial for STAT3(S727) phosphorylation and for NF-κB/STAT3-enhanced interleukin-6 expression. Furthermore, the intracellular HAK accumulation is strongly dependent on eEF1A1 expression. Taken together, the results reveal a novel molecular mechanism for a non-canonical role of eEF1A1 in signal transduction via direct modulation of kinase-dependent phosphorylation events.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Eukaryotic elongation factor 1A1; Interleukin-6; Protein kinase Cδ; STAT3

Mesh:

Substances:

Year:  2014        PMID: 24487064     DOI: 10.1016/j.bbamcr.2014.01.022

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells.

Authors:  Xingju Zhang; Fei Li; Ying Tang; Qinglan Ren; Bin Xiao; Ying Wan; Shan Jiang
Journal:  Oncogene       Date:  2020-08-27       Impact factor: 9.867

2.  [Eukaryotic translation elongation factor 1A1 positively regulates NOB1 expression to promote invasion and metastasis of hepatocellular carcinoma cells in vitro].

Authors:  Wenming Zhang; Mingfeng Xiang; Chuqian Zheng; Leifeng Chen; Jin Ge; Chen Yan; Xiuxia Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-09-30

3.  MLIF Alleviates SH-SY5Y Neuroblastoma Injury Induced by Oxygen-Glucose Deprivation by Targeting Eukaryotic Translation Elongation Factor 1A2.

Authors:  Qiuzhen Zhu; Yuefan Zhang; Yulan Liu; Hao Cheng; Jing Wang; Yue Zhang; Yaocheng Rui; Tiejun Li
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

4.  RNA expression and disease tolerance are associated with a "keystone mutation" in the ochre sea star Pisaster ochraceus.

Authors:  V Katelyn Chandler; John P Wares
Journal:  PeerJ       Date:  2017-08-15       Impact factor: 2.984

5.  CagA orchestrates eEF1A1 and PKCδ to induce interleukin-6 expression in Helicobacter pylori-infected gastric epithelial cells.

Authors:  Shaohan Xu; Xiaoqian Wu; Xiaoyan Zhang; Chu Chen; Hao Chen; Feifei She
Journal:  Gut Pathog       Date:  2020-07-03       Impact factor: 4.181

6.  EEF1A1 deacetylation enables transcriptional activation of remyelination.

Authors:  Mert Duman; Adrien Vaquié; Gianluigi Nocera; Manfred Heller; Michael Stumpe; Devanarayanan Siva Sankar; Jörn Dengjel; Dies Meijer; Teppei Yamaguchi; Patrick Matthias; Thomas Zeis; Nicole Schaeren-Wiemers; Antoinette Hayoz; Sophie Ruff; Claire Jacob
Journal:  Nat Commun       Date:  2020-07-09       Impact factor: 14.919

Review 7.  Functions and Regulation of Translation Elongation Factors.

Authors:  Benjin Xu; Ling Liu; Guangtao Song
Journal:  Front Mol Biosci       Date:  2022-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.